Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...
Science publication describes the discovery and preclinical characterization of small molecules that inhibit RAS-dependent PI3K oncogenic signaling.
NOTE. P < .00357 represents statistical significance after the Bonferroni correction. Abbreviations: MAPK, mitogen-activated protein kinase; NA, unable to be calculated; NR, not reached; OS, overall ...